Theragnostic Talks

We need to increase knowledge and awareness of theragnostics and now is the time. That's the view of Lucy Morgan, associate director of research and policy at the Health Policy Partnership. But how do we do that?  Listen to her talk about it and the Radioligand Therapy Readiness Hub.

“People don’t have to reinvent the wheel, not start from scratch. They can get great ideas and take advantage of hard work that has already been done”.

New episode of Theragnostic Talks out now!

Guest: Lucy Morgan

By: Lisa Gruschy and Gustav Widar

Contact us: [email protected]

For more info, visit www.samnordic.se

The world is on its way of taking a giant leap forward in the field of theragnostics. But are we ready for it? In this episode of Theragnostic Talks, we discuss readiness and the best way to raise awareness of theragnostics. How do we develop the field? And how do we expand the nuclear medicine practice to meet this challenge?

Guests: Adj. Prof. Cristina Nanni, Prof. Andrei Iagaru, Prof. Louise Emmett, and Jeevan Virk, Head of RLT at Novartis.

By: Gustav Widar, Medical Affairs Manager at SAM Nordic

Contact us: [email protected]

For more information, visit: www.samnordic.se

What is it with FAPI and how does it work? In this episode of Theragnostic Talks, we take a closer look at the tracer that everyone’s talking about. The new theragnostic tracer targets the tumour environment and can be used for both the diagnosis and treatment of a wide range of different types of cancers. Explaining this are Dr. Wolfgang Fendler, Prof. Thomas Hope, Kim M. Pabst, and Silvi Telo.

Guests: Dr. Wolfgang Fendler, Prof. Thomas Hope, Kim M. Pabst, and Silvi Telo.

By: Gustav Widar, Medical Affairs Manager

Contact us: [email protected]

For more information, visit: www.samnordic.se

How do we move forward with prostate imaging? In today’s episode of Theragnostic Talks, live from the EANM'22 Congress in Barcelona, we focus on PSMA-PET. How has PSMA-PET developed? Where are we regarding the diagnosis of prostate cancer? And how can we use PSMA-PET as a diagnostic tool for other forms of malignant tumours? Our thanks to Prof. Helle Damgaard Zacho, Dr. Daniela Oprea-Lager, and Simona Malaspina for sharing your expertise with us.

Guests: Prof. Helle Damgaard Zacho, Dr. Daniela Oprea-Lager and Simona Malaspina.

By: Gustav Widar, Medical Affairs Manager at SAM Nordic

Contact us: [email protected]

For more information: www.samnordic.se

What is EANM? What have been the most burning questions through the years and in what ways do we want to move forward in this area? Theragnostic Talks will be live in Barcelona to talk with the leading experts in theragnostics. We start by taking a closer look at the journey that nuclear medicine has taken lately, and we will be doing this in the company of Prof. Jolanta Kunikowska, President of EANM, and Prof. Stefano Fanti, EANM Congress Chair.

Guests: Prof. Jolanta Kunikowska and Prof. Stefano Fanti

By: Gustav Widar, Medical Affairs Manager

Contact us: [email protected]

For more information: www.samnordic.se

LuTectomy – LuPSMA in the very early stage of prostate cancer – what were the initial results? What difference does it make, choosing the right PSMA tracer? And how should PSMA-PET be used, according to the radiation oncologist? Listen to our eminent guests Declan Murphy, Stefano Fanti, Louise Emmett, Gert de Meerleer and Ken Herrmann talking about the future of theragnostics in urology, from the EAU 22 Congress in Amsterdam.

Guests: Ken Herrmann, Gert de Meerleer, Louise Emmett, Stefano Fanti and Declan Murphy.

By: Lisa Gruschy and Gustav Widar

Contact us: [email protected]

For more info, visit www.samnordic.se

Using biomarkers from a blood test: can that optimize the treatment for prostate cancer? Listen to Professor Henrik Grönberg, who recently received the award “Cancer Researcher of the Year in 2022” by the Swedish Cancer Society. He tells us about the ProBio study which has the potential to revolutionize the treatment of prostate cancer.

– I tell my kids that I am probably not going to see them a lot but I am going to do stuff for a lot of patients out there who are living miserable lives. That is my motivation, to make somebody feel better.

In this episode of Theragnostic Talks we get to meet Dr Laura Ravasi. She is Head of Global Medical Affairs at Telix Pharmaceuticals and travels all over Europe to find out more about the challenges and possibilities of tomorrow. Join us on the journey, from proof of concept to theragnostics of today.

Guest: Dr Laura Ravasi

By: Annette Andren and Gustav Widar

Contact us: [email protected]

For more info, visit www.samnordic.se

When she found boxes of her father´s original work, Barbara Hertz decided to put all the puzzle pieces together. This episode of Theragnostic Talks is about Saul Hertz, the father of theragnostics. Saul Hertz was the first medical doctor to use radioactive iodine to treat hyperthyroidism, he pioneered the first targeted cancer therapies. Listen to his daughter Barbara telling us about his discoveries and insights, his eureka moment and about the fact that other people took credit for his work.

Guest: Barbara Hertz

By: Annette Andrén and Gustav Widar

Contact us: [email protected]

For more info, visit www.samnordic.se